Evidence map›Paper›PMID 40972944›Full record

ReviewMolecular metabolism2025

Are we giving too much weight to lean mass loss?

Jeffery Bolte, Annie A Smelter, Luke Norton

Abstract readReview
In one paragraph

Review in Molecular metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Genetically Predicted Muscle Mass and Function in Relation to Deep Vein Thrombosis: A Two-step Mendelian Randomization Study Highlighting the Mediating Role of BMI.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeffery BolteDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Annie A SmelterDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Luke NortonDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA; Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA. Electronic address: nortonl@uthscsa.edu.

Funding

ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WALSH, NICOLAS EUGENE · 1985 to 2008
$23.1M
SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · YALE UNIVERSITY · PI RALPH A DEFRONZO · 1986 to 2026
$12.7M
SGLT2 Inhibition and Stimulation of Endogenous Glucose ProductionR01DK107680 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO · 2016 to 2026
$5.9M
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican AmericansU01DK085524 · NIDDK · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI BLANGERO, JOHN, DEFRONZO, RALPH A · 2009 to 2019
$5.9M
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizersR01DK129676 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO, Luke Norton · 2022 to 2026
$3.4M
The Regulation of Hepatic Metabolic Zonation by the Diabetes Gene TCF7L2R01DK128247 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Luke Norton · 2022 to 2026
$2.3M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM145432 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jose E Cavazos, Ratna K Vadlamudi · 2023 to 2026
$2.3M
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DMR01DK103841 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DEFRONZO, RALPH A · 2015 to 2017
$1.5M
Improved Hypoglycemia Rescue DeviceR44DK085809 · NIDDK · XERIS PHARMACEUTICALS, INC. · PI DEFRONZO, RALPH A, KINZELL, JOHN · 2011 to 2012
$994k
Regulation of Hepatic and Peripheral Glucose MetabolismR56DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DEFRONZO, RALPH A · 2005 to 2005
$73k
CSRD VA I01 CX001389NCRR NIH HHS M01 RR001346NIDDK NIH HHS R01 DK024092NIDDK NIH HHS R01 DK103841NIDDK NIH HHS R01 DK107680NIDDK NIH HHS R01 DK128247NIDDK NIH HHS R01 DK129676NIDDK NIH HHS R44 DK085809NIDDK NIH HHS R56 DK024092NIDDK NIH HHS U01 DK085524NIGMS NIH HHS T32 GM145432
6 · The paper itself

Abstract

The global rise in obesity has underscored the critical importance of body composition, particularly the balance between fat mass and lean mass, in determining health outcomes. While excess fat mass is a well-established risk factor for numerous chronic diseases and reduced longevity, lean mass preservation has been widely considered essential for mitigating fall risk and maintaining functional independence. Recent advances in incretin-based weight loss therapies have shown remarkable efficacy in reducing body weight but have raised concerns about the concomitant loss of lean mass. However, emerging evidence suggests that muscle quality - rather than absolute muscle mass - is a more robust predictor of functional capacity and all-cause mortality. Intriguingly, these therapies may enhance muscle quality even while promoting lean mass loss, offering a nuanced perspective on their impact. This review aims to synthesize current evidence on body composition, muscle quality, and weight loss therapies to guide clinicians in tailoring weight loss strategies that optimize both metabolic health and patient outcomes.

Indexed as

ObesityWeight LossBody CompositionHumansIncretinsMuscle, SkeletalIncretinsAgingBody compositionGLP-1 receptor agonistMuscleObesitySarcopenia

Identifiers

PMID40972944
PMCPMC12506580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.